Abstract: Provided are pyrrolyl substituted dihydroindol-2-one derivatives represented by formula (I), pharmaceutically acceptable salts or solvates of said derivatives, or solvates of said salts, which are effective tyrosine kinase inhibitors. Also provided are the preparation methods of the above compounds, pharmaceutical compositions containing these compounds, and the use of these compounds in manufacturing drugs useful for the treatment or adjunctive treatment of tumors medicated by tyrosine kinases or proliferation or migration of tumor cells driven by tyrosine kinases in mammals (including human).

Abstract: Provided are pyrrolyl substituted dihydroindol-2-one derivatives represented by formula (I), pharmaceutically acceptable salts or solvates of said derivatives, or solvates of said salts, which are effective tyrosine kinase inhibitors. Also provided are the preparation methods of the above compounds, pharmaceutical compositions containing these compounds, and the use of these compounds in manufacturing drugs useful for the treatment or adjunctive treatment of tumors medicated by tyrosine kinases or proliferation or migration of tumor cells driven by tyrosine kinases in mammals (including human).

Abstract: The invention relates to sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones compounds having formula (I) wherein R1 is selected from the group consisting of 4-methylsulfonyl, 4-aminosulfonyl, hydrogen, 2-, 3-, or 4-halogen, C1–C6-alkyl, cyclopentyl, cyclohexyl, C1–C4-alkoxy, hydroxy, cyano, nitro, amino or trifluoromethyl; R2 is selected from the group consisting of 4-methylsulfonyl, 4-aminosulfonyl, hydrogen, 2-, 3-, or 4-halogen, C1–C6-alkyl, cyclopentyl, cyclohexyl, C1–C4-alkoxy, hydroxy, cyano, nitro, amino or trifluoromethyl; and R3 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, i-propyl, c-propyl, n-butyl, isobutyl; provided that when R1 is a methylsulfonyl or aminosulfonyl group, R2 is any group as defined above except a methylsulfonyl or aminosulfonyl group; and when R2 is a methylsulfonyl or aminosulfonyl group, R1 is any group as defined above except a methylsulfonyl or aminosulfonyl group, also to processes for the preparation of such compounds, to pharmaceutical co

Abstract: The invention discloses use of benzisoselenazolones, particularly compounds represented by the general formula (I) against ischemic myocardial injury. The compounds are characterized by selectively inhibiting Na+/Ca2+ exchange, dilating coronary artery and decreasing myocardial oxygen consumption, which possess the advantages of high activity, potent specificity and low toxicity.

Abstract: The present invention relates to sulfonyl-containing 2,3-diarylindole, especially to new compounds of general Formula, to a preparation method for their preparation, to pharmaceutical compositions containing said compound, and to the medical use thereof in the treatment of diseases relating to the inhibition of cyclooxygenase-2 (COX-2).

Abstract: The present invention relates to sulfonyl-containing 2,3-diarylindole, especially to new compounds of general Formula, to a preparation method for their preparation, to pharmaceutical compositions containing said compound, and to the medical use thereof in the treatment of diseases relating to the inhibition of cyclooxygenase-2 (COX-2).

Abstract: The invention relates to sulfonyl-containing 3,4-diaryl-3-pyrrolin-2-ones compounds having formula (I) 1

Abstract: The invention relates to compounds of formula (I): wherein R1 represents alkyl or ureido, R2 represents alkyl or hydrogen, or R1 and R2 together form a 5- or 6-membered ring, R3 represents CN, NO2, NRaR′a, NRaSO2R′a, NRaCZR5 or CZNRaR′a, R4 represents hydrogen or R3, and medicinal products containing the same which are useful in treating or preventing epilepsy and neurodegenerative diseases.

Abstract: The invention relates to compounds of formula (I): wherein R1 represents an alkyl or ureido group, R2 represents an alkyl group or a hydrogen atom, or R1 and R2 together form a 5- or 6-membered ring, R3 represents a group CN, NO2, NRaR′a, NRaSO2,R′aCZR5 or CZNRaR′a, R4 represents a hydrogen atom or a group R3.